(Q42628866)

English

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

scientific article published on 13 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

phase II clinical trial

0 references

multicenter clinical trial

0 references

post-transplant lymphoproliferative disorder

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Heiner Zimmermann

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Franck Morschhauser

11

object named as

Franck Morschhauser

1 reference

Europe PubMed Central

18 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

author name string

Stephan Oertel

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Veronique Leblond

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Monica Sender

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ruth Neuhaus

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hans Lehmkuhl

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Heinz August Horst

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Thierry Lamy

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Malte Leithäuser

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ioannis Anagnostopoulos

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Martine Raphael

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Hanno Riess

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sylvain Choquet

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

German PTLD Study Group

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

European PTLD Network

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Petra Reinke

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

13 December 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

196-206

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant lymphoma--a single-center experience of 500 liver transplantations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of PTLD with rituximab or chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interindividual variability of response to rituximab: from biological origins to individualized therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970300-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70300-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22173060%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42628866&oldid=2120326212"